LEADER 03104nam  2200769z- 450 
001 9910557602603321
005 20210501
035   $a(CKB)5400000000045377
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69310
035   $a(oapen)doab69310
035   $a(EXLCZ)995400000000045377
100   $a20202105d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aHost-Directed Therapies for Tuberculosis
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (120 p.)
311 08$a3-03943-501-9 
311 08$a3-03943-502-7 
330   $aTB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB.
606   $aBiology, life sciences$2bicssc
606   $aResearch & information: general$2bicssc
610   $aantioxidants
610   $aantiplatelet
610   $aaspirin
610   $aautophagy
610   $aBCG vaccination
610   $aco-infections
610   $aco-morbidities
610   $acytokines
610   $agene expression
610   $aglutathione
610   $agranulomas
610   $ahost-directed therapies
610   $aimmune exhaustion
610   $aimmune response
610   $aimmune responses
610   $aimmunomodulation
610   $ainflammation
610   $ainvasive procedure
610   $airon supplementation
610   $alatent infection
610   $alung cancer
610   $aM. tb
610   $amisdiagnosis
610   $aMycobacterium tuberculosis
610   $apathology
610   $aPerls' stain
610   $apulmonary
610   $arabbit
610   $aredox imbalance
610   $arevising
610   $asurvival
610   $aTaiwan
610   $atuberculosis
610   $atype 2 diabetes
615  7$aBiology, life sciences
615  7$aResearch & information: general
700   $aVenketaraman$b Vishwanath$4edt$01303388
702   $aVenketaraman$b Vishwanath$4oth
906   $aBOOK
912   $a9910557602603321
996   $aHost-Directed Therapies for Tuberculosis$93026986
997   $aUNINA